-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is from NEJM Journal Watch
Zinc for Patients with COVID-19?
Do people with COVID-19 need to take zinc preparations?
Reviewed by Daniel Kaul, MD
In a randomized, blinded, multicentre study in Tunisia, oral zinc formulations appeared to be beneficial in reducing COVID-19 progression, particularly in critically ill hospitalized patients
.
Since the onset of the COVID-19 pandemic, there have been several preliminary reports suggesting that various repurposed drugs or vitamins (e.
g.
, vitamin C, hydroxychloroquine) may improve patient outcomes, but these reports have not been confirmed
in larger randomized studies.
This time, the researchers reported the results
of a randomized trial of zinc preparations.
From 15 February to 4 May 2022, 470 patients attending the COVID-19 triage area of five hospitals in Tunisia were randomized into two groups, either with a zinc preparation orally (25 mg twice daily) or placebo for 15 days
.
Patients with severe comorbidities, requiring assisted ventilation, or symptoms lasting more than 7 days were excluded
.
The mean age of patients was 54 years, 60% required supplemental oxygen at the time of trial inclusion, and 23% had received at least one dose of COVID-19 vaccine
.
At 30 days, the primary composite outcome (admission to ICU or death) was 10.
4% and 16.
7%,
respectively, in the zinc and placebo groups.
Patients in the zinc preparation group had a shorter hospital stay than the placebo group
.
Outpatients receiving zinc reported a shorter duration of symptoms, but there was no reduction
in those requiring hospitalization.
comments
Most COVID-19 trials included critically ill hospitalised patients, or mild to moderate outpatients
.
The study included both populations, making the results more difficult to interpret.
Because high mortality and high ICU hospitalization rates no longer exist, confirmatory studies
are difficult.
I wouldn't recommend zinc in hospitalized patients with COVID-19 (and certainly not for proven regimens for COVID-19 of any severity), but it doesn't seem to hurt if a patient or clinician wants to try zinc on top of other proven regimens, and there is some scientific evidence
now.
Articles that were commented on
Ben Abdallah S et al.
Twice-daily oral zinc in the treatment of patients with coronavirus disease 2019: A randomized double-blind controlled trial.
Clin Infect Dis 2022 Nov 4; ciac807; [e-pub].
(https://doi.
org/10.
1093/cid/ciac807)
A collection of NEJM journals
NEJM Journal Watch is published by NEJM Group, inviting internationally renowned doctors to review important papers in the field of medicine and help doctors understand and apply the latest progress.
"NEJM Medical Frontiers" is translated several times a week, published on the app and official website, and 2-3 selected articles are published
on WeChat.
Copyright InformationThis article was translated, written or commissioned by Jiahui Medical Research and Education Group (J-Med) in collaboration with the New England Journal of Medicine (NEJM) for NEJM Medical Frontiers
.
The full text of the Chinese translation and the figures contained therein are exclusively licensed
by NEJM Group.
If you want to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement and the copyright owner reserves the right to
pursue legal liability.